ASX Announcement

Recce Pharmaceuticals
recce.com.au
ACN 124 849 065

Placement Settlement Successfully Completed

Highlights:

- **Settlement successfully completed for A$5.0 million Placement at A$0.28 per share to an existing Australian-based private investor**
- **Funds will be used to support Phase 3 Diabetic Foot Infection (DFI) Registrational Topical Clinical Trial in Indonesia and Phase 3 Acute Bacterial Skin and Skin-Structure Infections (ABSSSI) Registrational Topical Clinical Trial in Australia**
- **Pro-rata, non-renounceable 1-for-6 Entitlement Offer to raise up to A$10.8 million to open on 22 April 2025**

Sydney, Australia, 17 April 2025: Recce Pharmaceuticals Limited (**ASX:RCE, FSE:R9Q**) (**Recce** or the **Company**), a leading developer of a new class of Synthetic Anti-Infectives, is pleased to announce that settlement of the A$5.0 million placement of new fully paid ordinary shares in the Company (**Placement**) to an existing Australian-based private investor has successfully completed.

Funds raised from the Placement will be used to support Phase 3 DFI Registrational Topical Clinical Trial in Indonesia and Phase III ABSSSI Registrational Topical Clinical Trial in Australia.

As announced on 10 April 2025, Recce is also conducting a pro-rata, non-renounceable 1-for-6 entitlement offer to raise up to A$10.8 million, opening on Tuesday, 22 April 2025 (**Entitlement Offer**). Shares offered under the Entitlement Offer will be issued at A$0.28 per share, the same price at the Placement. The Entitlement Offer Booklet and personalised entitlement and acceptance forms are expected to be dispatched to eligible shareholders on Tuesday, 22 April 2025. For further information on the Entitlement Offer, please refer to the announcement released to the ASX on 10 April 2025.

This announcement has been approved for release by Recce Pharmaceuticals Board.

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs.

Recce's anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE® 529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce's anti-infectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics.

The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens, recognising Recce's efforts to combat antimicrobial resistance. The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval. R327 is also included on The Pew Charitable Trusts' Global New Antibiotics in Development Pipeline as the sole synthetic polymer and sepsis drug candidate in development.

Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce's anti-infective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.

recce.com.au
ACN 124 849 065

Media and Investor Relations

Chief Executive Officer
James Graham
Recce Pharmaceuticals Ltd
james.graham@recce.com.au

Australia
Andrew Geddes
Seed Media
andrew@seedmedia.com.au

USA
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com

Europe
Guillaume van Renterghem
LifeSci Advisors
gvanrenterghem@lifesciadvisors.com